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Summary
Lysine acetylation of human tumor suppressor p53 in
response to cellular stress signals is required for its
function as a transcription factor that regulates cell cy-
cle arrest, senescence, or apoptosis. Here, we report
small molecules that block lysine 382-acetylated p53
association with the bromodomain of the coactivator
CBP, an interaction essential for p53-induced tran-
scription of the cell cycle inhibitor p21 in response to
DNA damage. These chemicals were discovered in
target structure-guided nuclear magnetic resonance
spectroscopy screening of a focused chemical library
constructed basedon the structural knowledge of CBP
bromodomain/p53-AcK382 binding. Structural charac-
terization shows that these chemicals inhibit CBP/p53
association by binding to the acetyl-lysine binding site
of the bromodomain. Cell-based functional assays de-
monstrate that the lead chemicals can modulate p53
stability and function in response to DNA damage.
Introduction
The human tumor suppressor p53 is a transcription fac-
tor that binds in a sequence-specific manner to particu-
lar sites in the genome and activates transcription of tar-
get genes [1–3]. It plays a pivotal role in cellular response
to stress signals in cell cycle arrest, senescence, DNA re-
pair, or apoptosis [4–7]. The biological activity of p53 is
tightly regulated by posttranslational modifications in
its N- and C-terminal regions [1, 6, 8]. Upon DNA damage,
p53 is extensively phosphorylated within the N-terminal
activation domain, which relieves it from association
with the negative regulator Mdm2, resulting in p53 stabi-
lization and activation [9–11]. In addition, phosphoryla-
tion occurs in the C terminus of p53, which has been sug-
gested to enhance its DNA binding in vitro [12, 13].
In response to extracellular stress or DNA damage,
p53 becomes acetylated on multiple lysine residues at
its C terminus [14–16]. Particularly, the transcriptional
coactivator histone acetyltransferase p300/CREB bind-
ing protein (CBP) has been shown to acetylate K373,
K382, and, to a lesser extent, K372 and K381, whereas
another coactivator, p300/CBP-associated factor (PCAF),
acetylates K320. The dynamic interplay between lysine
*Correspondence: ming-ming.zhou@mssm.eduacetylation and deacetylation of p53 has been directly
linked to its ability to regulate p53 stability or protein level
in cells as well as functional activation as a transcription
factor in cell cycle arrest, apoptosis [17–21], and senes-
cence [22]. It was hypothesized on the basis of in vitro
data that p53 acetylation enhances its DNA binding
through the relief of negative regulation of DNA binding
exerted by the C-terminal region [14–16]. However,
more recent cell-based studies show that lysine acet-
ylation of p53 may not result in direct enhancement of
its DNA binding ability [14–16], but rather promotes its re-
cruitment of transcriptional coactivators, which leads to
subsequent histone acetylation of chromatin and tran-
scriptional activation of its target genes [20]. Indeed,
our recent study shows that acetylated K382 in p53
serves as a binding site for the CBP bromodomain
(BRD), and that this BRD/acetyl-lysine (AcK) binding is
responsible for p53 acetylation-dependent coactivator
recruitment after DNA damage, a step that is essential
for p53-induced transcriptional activation of the cyclin-
dependent kinase inhibitor p21 in G1 cell cycle arrest
[23].
Despite the fact that these posttranslational modifica-
tions are known to play an important role in p53 function,
specific effects of single or combinatorial modifications
on p53 function remain elusive. Because many of these
modifications are clustered within a relatively short
stretch of the protein sequence, conventional point mu-
tational analysis of one modification site can lead to
masking of effects exerted by different neighboring mod-
ifications. To circumvent this problem, we aimed to de-
velop small-molecule chemical ligands that are capable
of selectively modulating molecular interactions and reg-
ulation of p53 function involving these modifications,
particularly lysine acetylation. Such small molecules
can be used to study endogenous p53 and its effector
proteins in cell-based assays, which may help us gain
mechanistic insights into the effects of single or combi-
natorial modifications on p53 activation in response to
DNA damage.
In this study, we report the identification of a series of
small-molecule chemical compounds that can block
K382-acetylated p53 association with the BRD of CBP.
These small molecules were discovered in target struc-
ture-based nuclear magnetic resonance (NMR) spec-
troscopy screening of a focused library of chemical com-
pounds that was constructed based on the structural
knowledge of the CBP BRD/p53-AcK382 interaction.
Our structure-based characterization, using combined
experimental and computational methods, shows that
some of these small-molecule compounds can effec-
tively inhibit CBP/p53 association by specifically binding
to the AcK binding pocket of the CBP BRD. Cell-based
functional assays further demonstrate that the lead
chemicals can modulate p53 stability, protein level, and
modification patterns, as well as transcriptional activa-
tion of downstream target gene p21 in response to DNA
damage. The combined in vitro and in vivo studies with
these small molecules also help in selection of ligand
for further lead optimization.
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AcK Binding Sites in the CBP and PCAF
BRDs
(A) Ribbon diagram of the 3D structure of the
CBP BRD in complex with lysine 382-acety-
lated p53 peptide (PDB 1JSP).
(B and C) Surface electrostatic potential rep-
resentation of the BRDs of CBP and PCAF,
respectively. The electrostatic potential of the
protein molecular surface was calculated using
Delphi [47], and figures were produced using
GRASP [49] and rendered using Pov4Grasp
(http://pov4grasp.free.fr/).
(D and E) 3D representations of electrostatic
isopotential contours of the CBP and PCAF
BRDs. Contours are drawn at 21KB/T (red)
and +1KB/T (blue). The electrostatic potential
was calculated using Delphi [47] and the fig-
ure was made using UCSF Chimera [48].Results and Discussion
Knowledge-Based Design of a Focused Library
NMR-based screening of chemical compounds for
a given target protein is considered to be reliable and
target site-specific, making it preferable over random
high-throughput screening [24–27]. However, because
of relatively slow speed of NMR spectral acquisition and
requirement of significant amount of protein samples,
NMR is generally not best suited for chemical screening
in a high-throughout fashion. To circumvent this short-
coming, we have employed a strategy that combines a
target structural knowledge-based construction of a ‘‘fo-
cused’’ library and NMR screening for lead identification.
In designing a library, diversity of chemical com-
pounds plays an important role in the successful out-
come of screening [28]. Although a desirable property,
chemical diversity is not the sole criterion; and pure di-
versity emphasis may bias libraries away from preferred
drug properties [29, 30]. Need of chemical diversity cov-
erage for successful lead identification, however, is in-
versely proportional to available structural and func-
tional knowledge for a given target.
The BRD is found in a large number of chromatin-asso-
ciated proteins and nuclear histone lysine acetyltrans-
ferases (HATs), and has been recently shown to function
as an AcK binding domain [31]. BRD/AcK binding plays
a pivotal role in regulation of chromatin remodeling and
gene transcription [32, 33]. BRDs adopt a conserved
structural fold of a left-handed four-helix bundle (aZ, aA,
aB, and aC), as first shown in the PCAF BRD [34]. The ZA
and BC loops at one end of the bundle form a hydropho-
bic pocket for AcK binding. The structure of the CBP
BRD bound to a p53-AcK382 peptide [23] shows thatAcK382 intercalates into the protein hydrophobic cavity
and interacts with residues of the ZA and BC loop (Fig-
ure 1A). The structures of PCAF BRD/HIV Tat-AcK50
[35] and GCN5p BRD/H4-AcK16 [36] complexes confirm
that the residues in BRDs important for AcK recognition
are largely conserved, whereas sequence variations in
the ZA and BC loops with amino acid deletion or insertion
enable discrimination of different binding targets.
The AcK binding pocket is hydrophobic in nearly all
BRDs, whereas electrostatics at the opening of the AcK
binding pocket displays significant variations in different
BRDs. For example, in CBP BRD, the opening is slightly
positively charged, while it is more negatively charged in
PCAF BRD (Figure 1B versus 1C and 1D versus 1E).
These differences at the ligand binding site could serve
as the basis for selectivity of chemical ligands targeting
a particular BRD. Given these structural feature differen-
ces at the AcK binding pocket and the fact that most
known drug molecules contain one aromatic ring, we
constructed a knowledge-based library of w200 com-
pounds from a collection of w14,000 small molecules
(ChemBridge Corporation, San Diego, CA). The following
criteria were used for the compound selection: (1) each
compound consists of one aromatic ring connected to a
2NHCOCH3 group, either directly or via a two-three car-
bon chain; and (2) drug-like properties of compounds are
evaluated according to the Lipinsky’s Rule of Five [37].
Lead Identification by NMR
We divided the library of 200 compounds into 25 screen-
ing mixtures, with each containing eight compounds.
Ligand binding to the protein was detected by monitor-
ing chemical shift changes of protein backbone amide
resonances in 2D 1H-15N-HSQC spectra acquired in the
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83Figure 2. Discovery of Initial Lead Compounds for the CBP BRD
(A) Small-molecule compounds that bind to the CBP BRD.
(B) Superposition of 2D 1H-15N-HSQC spectra of the CBP BRD showing changes of the protein NMR resonances from the free form (black) to
the complex form, with a representative compound, MS2126.
(C) Weighted 1H and 15N chemical shift changes (Dd) by the CBP BRD induced by binding to representative ligands from each group (i.e.,
MS2126, MS7972, MS9802, or MS0433). The AcK binding site lies between ZA and BC loops. Amino acid residues exhibiting major chemical
shift perturbations are color-coded on the protein surface: red for 0.05 ppm < Dd < 0.08 ppm; and blue for Dd > 0.08 ppm. The orientation of the
protein structure is similar to that in Figures 1A and 1B.
(D) Stack plot of absolute changes in chemical shift (DdX = dX+ ligand2 d
X
Free, where X is
1H or 15N) in the presence of four Group D compounds,
along the 1H or 15N dimension. Note that directionality of chemical shift perturbations for each compound is the same.presence and absence of screening mixture; positive
mixtures were then deconvoluted to identify individual
binding ligands. From this knowledge-based library,
we have identified 14 compounds that bind to the CBP
BRD (Figure 2A). All of these ligands (except the
MS5611) showed selective binding to CBP BRD, as
they did not show any binding to the structurally similar
PCAF BRD (data not shown). A weighted chemical shift
perturbation Dd,
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;of protein residues was used to characterize small-
molecule binding to the protein. As the protein residues
that exhibited the most significant ligand-induced chem-
ical shift perturbations are largely located in the ZA and
BC loops (Figure 2C, lower panel), it is possible that all
these compounds bind near the AcK binding site (Fig-
ure 2C, upper panel).
We classified these 14 compounds into 4 groups
on the basis of their chemical structures (Figure 2A):
(1) Group A compounds contain one aromatic ring
fused to an alicyclic ring; (2) Group B compounds have
two fused aromatic rings; (3) Group C compounds have
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84Figure 3. Structural Analysis of CBP BRD In-
teractions with Small Molecules
(A) Identification of binding locations of small
molecules in the CBP BRD by Autodock 3.0
calculations (left panels) and J surface cal-
culations using NMR chemical shift pertur-
bation data at 2s (right panels). Ribbons dia-
grams depict best binding modes of ligands
of each group, as determined by Autodock
3.0 calculations. The aromatic ring of each
compound is color-coded according to the
corresponding J surface calculation.
(B) Three-dimensional structure of the CBP
BRD bound to MS7972, as determined by
NMR spectroscopy, illustrating the ligand
binding site between the ZA and BC loops.only one aromatic ring attached to a -NHCOCH3 group;
and (4) Group D compounds have one aromatic ring
substituted with -(CH2)2NHCOCH3.
The proper grouping of lead compounds provides
valuable insights into structure-activity relationships
(SAR) in their interaction with the CBP BRD. Consistent
with their similarity in chemical structures, directionality
of absolute changes in chemical shift perturbations
along the 1H or 15N dimension in the 2D HSQC spectra
was similar for compounds in a given group (e.g., Group
D [Figure 2D]). Frequency of protein residues perturbed
by different ligands in a given group highlights the im-
portance of certain residues in ligand recognition (see
Figure S1 in the Supplemental Data available with this
article online). For example, there are 11 residues in
the BRD, mostly located in the ZA or BC loop, perturbed
by all the ligands in Group A. While overall residues per-
turbed by ligands crossing different groups are different,
information of residues commonly perturbed by binding
to different ligands can reveal similarity and/or differ-
ence in modes of ligand binding, and thus help in lead
optimization. Taken together, these results indicate
that the mode by which the protein interacts with ligands
within one group is similar, thus justifying the classifica-
tion of these compounds.
Identification of Ligand Binding Sites
Localization of ligand binding site in a target protein by
chemical shift perturbation data alone is difficult, as a di-
rect correlation between chemical shift perturbations
and spatial proximity to a binding ligand can be masked
by ligands with large shielding and anisotropies, as well
as by effects of indirect conformational changes of the
protein. Two alternative computational approaches can
provide invaluable insights into the structural basis of
protein/ligand recognition by localizing the ligand bind-ing site in the target protein. First, computational dock-
ing calculation of 3D structure model of a ligand bound
in a given target protein; the resulting structure model
can be evaluated with chemical shift perturbation data
obtained in NMR binding. Second, calculation of elec-
tron current density surface (J surface) [38]—a method
that is based on the concept that the flow of electrons
(J) is responsible for NMR chemical shifts and chemical
shift perturbations.
Ligand docking into a target protein can be performed
using Autodock 3.0 [39], which uses a genetic search al-
gorithm as a global optimizer and energy minimization
as a local search method. Although as a grid-based
method, Autodock limits itself to a rigid model of a target
protein, ligand flexibility is allowed. To predict the best
docking mode for a given ligand, docking calculations
generate a number of clusters (i.e., solutions with pair-
wise rmsd of all atoms of 1.0 A˚) and rank of each docking
mode (cluster rank). Docking mode is selected from the
lowest-energy solution of a cluster corresponding to the
minimum docking energy. The Autodock calculations
show that the aromatic ring of almost all ligands is lo-
cated in the hydrophobic AcK binding site (Figure 3A,
left column). Most of the residues predicted to be inter-
acting with ligands in the ZA and BC loops were also
shown to be perturbed by NMR data. Notably, ligands
that cause major chemical shift perturbations in the pro-
tein (i.e., ‘‘good binders’’) generate fewer clusters than
ligands that cause minor chemical shift perturbations
(i.e., ‘‘poor binders’’), consistent with the notion that
the former has a consensus of a single binding mode.
While for a given ligand, ligand binding site in the BRD
protein predicted by Autodock calculation generally
correlates well with NMR chemical shift perturbation
data, limitations of the docked structure models likely
exist due to high mobility of the ZA and BC loops, as
Small Molecules that Modulate Human p53 Function
85assessed by the predicted NMR S2 order parameters of
N-HN vectors of the protein backbone amide that were
calculated with its structure (Figure S2) [40]. Because
the ZA and BC loops comprise the AcK binding site in
the CBP BRD, such high structural dynamics may cause
major conformational changes of the ligand binding site
when bound to different ligands.
Calculation of J surface using chemical shift perturba-
tion data can also help localize a ligand when bound to
a target protein [38]. This method calculates the center
of electron current density for a ligand aromatic ring us-
ing point-dipole that is represented as dot density (J sur-
face), where the highest dot density correlates to the
center of the ligand aromatic ring. The surface can, there-
fore, guide to locate the binding site for the aromatic ring
of the ligand. When chemical shift perturbations are not
caused by direct ligand binding, inconsistency between
calculated J surface and chemical shift perturbation (i.e.,
diffused dot-density) may be observed. Possibly due to
likely major conformational changes of the ZA and BC
loops induced by ligand binding, many ligands from dif-
ferent groups show diffused dot-density (Figure 3A,
right column). Nevertheless, the Group B ligands exhibit
excellent consistency between calculated J surface and
the observed chemical shift perturbation.
To validate the predicted ligand binding site for
the Group B ligands, we solved the three-dimensional
structure of the CBP BRD in complex with MS7972
(9-acetyl-2,3,4,9-tetrahydro-carbazol-1-one) by NMR.
As revealed by the structure (Figure 3B, Table S1), the li-
gand is bound in a site formed by residues largely in the
ZA loop at the entrance of the AcK binding pocket, con-
firming the computational prediction. Moreover, the
structure also shows that the ligand forms a network
of intermolecular hydrophobic and aromatic interac-
tions with Val1115, Leu1120, Ile1122, Tyr1125, and
Tyr1167, and that the acetyl and ketone groups with
Val1115 and Leu1120, and Gln1113, respectively. Be-
cause many of these residues are involved in interac-
tions with the p53-AcK382 peptide, binding of MS7972
to CBP BRD likely blocks the protein interaction with
an AcK-containing binding partner, such as p53 (see be-
low). Taken together, we show that combined use of
NMR chemical shift perturbation mapping with Auto-
dock and J surface calculations may rapidly establish
the most probable structures of a protein bound to a li-
gand. Such model structures of protein/ligand com-
plexes are important for rational design of pharmaco-
phore and combinatorial libraries for lead improvement
to optimize potency and ligand binding selectivity of ini-
tial leads for a specific target protein.
Inhibition of CBP BRD/p53-AcK382 Interactions
by Lead Compounds
To evaluate whether these lead compounds are capable
of blocking CBP BRD binding to lysine 382-acetylated
p53, we performed an inhibition study. In this assay,
a chemical ligand in a concentration-dependent manner
competes against binding of the biotinylated p53-
AcK382 peptide immobilized on streptavidin-agarose
to the GST-fusion CBP BRD, as assessed by anti-GST
Western blot. As shown in Figure 4A, while MS9802
and MS0433 showed relatively little inhibition activity
against CBP BRD/p53-AcK382 association in a ligandconcentration of 5–100 mM, MS2126 and MS7972 can al-
most completely block this BRD interaction at 100 mM
and 50 mM, respectively. The inhibition activity of MS7972
is about 3-fold higher than that of MS2126. We further
characterized binding affinity of the leading compound
MS7972 binding to the protein using fluorescence spec-
troscopy. Of three tryptophan residues in this BRD,
Trp1165 in the BC loop is nearest to the AcK binding
site. The intrinsic tryptophan fluorescence shows emis-
sion maxima at 350 nm, indicating that the tryptophans
are likely completely solvent-exposed. Addition of
MS7972 to the CBP BRD results in emission at 445 nm
and quenching of the CBP BRD due to resonance energy
transfer (Figure 4B). Upon saturation with MS7972, the
protein tryptophan fluorescence undergoes a red shift
Figure 4. Small-Molecule Inhibition of CBP BRD and p53-AcK382
Interaction
(A) Inhibition of CBP BRD and p53-AcK382 peptide binding by lead
compounds in a competition assay detected by anti-GST Western
blot. In this assay, a lead compound competes against the biotiny-
lated p53-AcK382 peptide that was immobilized on streptavidin-
agarose beads for binding to the GST CBP BRD. Concentration
of the biotinylated or the nonbiotinylated p53 peptide used in the
assay is 10 mM and 25 mM, respectively, whereas compound con-
centration ranges from 0 to 100 mM, as indicated.
(B) Fluorescence titration of CBP BRD binding to MS7972. Super-
imposition of fluorescence spectra of the CBP BRD (w5 mM) with
increasing amount of MS7972 (0–80 mM). Binding affinity was deter-
mined by monitoring fluorescence intensity change at 450 nm as
a function of ligand concentration (inset).
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sponse to DNA Damage by Small Molecules
(A) Increased p53 expression in response to
DNA damage agent doxorubicin treatment,
as illustrated with U2OS cells. Wild-type p53-
expressing U2OS cells were incubated with
0.1 mg/ml doxorubicin for the indicated time
(up to 24 hr) and then subjected to immuno-
blotting analysis with specific antibodies.
(B) Small-molecule inhibition of the increase
in p53 levels in response to DNA damage.
Wild-type p53-expressing U2OS cells were
either incubated with DMSO or treated with
20 or 200 mM of each small-molecule com-
pound for 16 hr. Cells were then further incu-
bated with 0.1 mg/ml doxorubicin for an addi-
tional 24 hr as shown. Cell lysates were then
subjected to immunoblotting with the indi-
cated antibodies.
(C and D) Modulation of p53 function in re-
sponse to DNA damage by MS2126 or
MS7972, respectively. Wild-type p53-ex-
pressing U2OS cells were either incubated
with DMSO or treated with 200 mM of
MS2126 or MS7972 for 16 hr. Cells were
then further incubated with 0.1 mg/ml doxo-
rubicin for the indicated times and then sub-
jected to immunoblotting analysis with spe-
cific antibodies.
(E) Compound MS2126 does not affect the
increase in HIF1a level in response to hyp-
oxia. Wild-type p53-expressing U2OS cells
were incubated in the absence or presence
of 200 mM of MS2126 for 16 hr. Cells were
then further incubated in either normoxic or
hypoxic conditions for an additional 24 hr as shown. Cell lysates were then subjected to immunoblotting with the indicated antibodies.
(F) Compound MS5557 does not affect p53 function in response to DNA damage, as demonstrated in wild-type p53-expressing U2OS cells
with experimental conditions similar to those in (C) and (D). The cells were treated with DMSO, MS7972 (200 mM), or MS5557 (200 mM) for
16 hr, and then further incubated with 0.1 mg/ml doxorubicin for 24 hr, and then subjected to immunoblotting analysis with specific antibodies.at 350 nm, suggesting the possible change in protein lo-
cal conformation upon ligand binding. Change of fluo-
rescent intensity at 445 nm as a function of ligand con-
centration was used to determine binding constant, KD,
to be 19.6 6 1.9 mM (mean 6 SD), which is consistent
with its inhibition activity (Figure 4A).
Modulation of p53 Function via Inhibition of
p53/CBP Binding by Small Molecules
We assessed the effects of these initial lead compounds
on p53 function as transcription activator in response to
DNA damage in a cell-based assay. Consistent with what
is reported in the literature, p53 expression in U2OS cells
is low in a resting state, likely due to its negative regula-
tion by Mdm2 through interaction with the N-terminal re-
gion of p53 (Figure 5A). Upon DNA damage stimulation
by doxorubicin treatment, p53 becomes phosphorylated
within the N-terminal activation domain including serine
15, relieving it from association with the negative regula-
tor Mdm2 and resulting in p53 stabilization and an in-
crease in protein level in the cell, as assessed by anti-
p53 and anti-p53-pSer15 Western blots. In response to
DNA damage, p53 also becomes acetylated on its C-ter-
minal lysine residues including lysine 382, promoting its
recruitment of the transcriptional coactivator CBP/p300
via BRD/AcK binding, which leads to histone acetylation
and transcriptional activation of target genes, such as
the cyclin-dependent kinase inhibitor p21 in cell cycle ar-rest [20, 23]. As shown in Figure 5B, treatment of U2OS
cells with MS2126 or MS7972 at 200 mM, prior to the
doxorubicin stimulation, results in a dramatic decrease
of the doxorubicin-induced p53 increase as compared
with the DMSO control. This is likely due to the possibility
that the lysine-acetylated p53 in a free state is not stable
in the cell, as it is subject to rapid deacetylation by his-
tone deacetylases and subsequent ubiqutination and
protein degradation by Mdm2 [21]. This effect is consis-
tent with the corresponding decrease in p53-mediated
p21 activation in response to doxorubicin-induced DNA
damage. Treatment of U2OS cells with compound
MS9802 or MS0433 showed much fewer effects, if any,
on p53 protein level and activation in cells, which is con-
sistent with their inability to inhibit CBP BRD/p53-
AcK382 association in vitro (Figure 4A). Further studies
at different time points after doxorubicin treatment
show that treatment of MS2126 (Figure 5C) as well as
MS7972 (Figure 5D) results in loss of p53 phosphoryla-
tion at Ser15 as well as acetylation at Lys382 (Figure 5C).
While generally in agreement, due to differences in
chemical stability and cell permeability for individual
compounds, the ligand concentration required for ef-
fects on p53 function in the cell-based assay appears
higher than that for in vitro inhibition activity (Figure 4A).
Although we cannot rule out possible effects of these
compounds on other biological proteins in the cell,
downregulation of p53 protein level and functional
Small Molecules that Modulate Human p53 Function
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exerted in a ligand concentration-dependent and doxo-
rubicin exposure time-dependent manner likely result
from their inhibitory activity in blocking CBP BRD/p53-
AcK382 binding. Particularly, MS2126 does not seem
to affect the upregulation of HIF1a under hypoxic condi-
tions (Figure 5E), and MS5557, which is a structural ana-
log of MS7972, but does not bind to the CBP BRD
(Figure S3), does not modulate p53 function under DNA
damage condition (Figure 5F), thus further highlighting
the specificity of MS2126 and MS7972 for p53 function.
Taken together, these results strongly suggest that inhi-
bition of CBP BRD/p53 at AcK382 by small-molecule
compounds can cause a dramatic inactivation of p53
transcriptional activity through promoting its protein
instability by changes of its posttranslational modifica-
tion states. Moreover, these cell-based assays provide
a valuable assessment of cell permeability and in vivo ef-
ficacy of these small-molecule compounds on p53 func-
tion as a transcriptional activator for its target genes,
which is essential for further lead optimization through
SAR-guided chemical modifications.
Significance
Molecular mechanisms underlying p53 function that
direct cellular responses to external stress signals
are undoubtedly complex. Here, we show that small
molecules designed to modulate specific molecular
function of p53 can be used as powerful tools to ex-
ploremechanistic underpinnings ofmolecular interac-
tions and regulation of p53 in physiological condi-
tions. We also demonstrate that the knowledge of the
structural andmolecular basis of lysine 382-acetylated
p53 interaction with the BRD of the coactivator CBP
greatly facilitates our ability to identify small-molecule
ligands for the target CBP BRD from NMR-based
screening of a ‘‘focused’’ library constructed using
a target structure-based approach. Our structure-
based understanding of target interactions with differ-
ent classes of the lead compounds lays a foundation
for rational design of pharmacophore and chemical
modifications for lead optimization of potency and
binding selectivity. The emerging results from the
cell-based study of p53 protein level and functional ac-
tivation using these small molecules can feed back to
the rational design to address issues of cell perme-
ation and stability of lead chemicals. The approach re-
ported here is applicable to rational design of small-
molecule ligands for other protein modular domains
that play an important role in regulation of a wide vari-
ety of cellular processes.
Experimental Procedures
Protein Sample Preparation
The BRD of CBP (residues 1082–1197) was expressed in Escherichia
coli BL21(DE3) cells in the pET15b vector (Novagen, San Diego, CA),
as described previously [23]. Isotope-labeled proteins were pre-
pared from cells grown on a minimal medium containing 15NH4Cl
with or without 13C6-glucose in H2O. The protein was purified by
nickel-IDA affinity chromatography, followed by thrombin cleavage
to remove an N-terminal poly-His-tag. GST-fusion BRD of CBP (res-
idues 1082–1197) was expressed in E. coli in the pGEX4T3 vector(Amersham Biosciences Corp., Piscataway, NJ), and purified with
a glutathione-sepharose column.
Chemical Screening by NMR Spectroscopy
All spectra were recorded at 25ºC on a Bruker 500 or 600 MHz NMR
spectrometer. The NMR data were processed and analyzed using
NMRPipe [41] and NMRView [42]. Typical protein solution for NMR
study contained the CBP BRD of 0.2 mM in 100 mM phosphate
buffer (pH 6.5), containing 5 mM perdeuterated DTT and 10%
2H2O. All chemical stocks were prepared at w0.35 M in perdeuter-
ated DMSO. Initial protein and compound binding by NMR was con-
ducted with mixtures of eight compounds; each compound was 1–
2 mM and deuterated DMSO was w3% (v/v). The ligand binding
was detected by observing ligand-induced chemical shift perturba-
tions of residues of the 15N-labeled protein recorded in 2D 1H-15N-
HSQC spectra. The positive mixtures were deconvoluted by screen-
ing individual compounds to identify the active compound. Deuter-
ated DMSO in the latter protein/ligand solution wasw0.8% (v/v), and
a reference spectrum of the protein with DMSO alone with the corre-
sponding concentration was collected for data analysis.
Protein Structure Determination by NMR
NMR samples contained the CBP BRD (0.5 mM) in complex with
a chemical ligand, MS7972 (w2 mM), in 100 mM phosphate buffer
(pH 6.5), containing 5 mM perdeuterated DTT and 0.5 mM EDTA in
H2O/
2H2O (9/1) or
2H2O. All NMR spectra were acquired at 30ºC on
a Bruker 500 or 600 MHz NMR spectrometer. The backbone 1H,
13C, and 15N resonances were assigned using 3D HNCACB and
HN(CO)CACB spectra. The side-chain atoms were assigned from
3D HCCH-TOCSY and (H)C(CO)NH-TOCSY data. The NOE-derived
distance restraints were obtained from 15N- or 13C-edited 3D NOESY
spectra. The 3JHN,Ha coupling constants measured from 3D HNHA
data were used to determine F-angle restraints. Slowly exchanging
amide protons were identified from a series of 2D 15N-HSQC spectra
recorded after H2O/
2H2O exchange. The intermolecular NOEs used
in defining the structure of the CBP BRD/ligand complex were de-
tected in 13C-edited (F1),
13C/15N-filtered (F3) 3D NOESY spectra
[43]. Protein structures were calculated with a distance geometry-
simulated annealing protocol with X-PLOR [44]. Initial structure cal-
culations were performed with manually assigned NOE-derived dis-
tance restraints. Hydrogen-bond distance restraints, generated
from the H/D exchange data, were added at a later stage of structure
calculations for residues with characteristic NOEs. The converged
structures were used for iterative automated NOE assignment by
ARIA for refinement [45]. Structure quality was assessed by Pro-
check-NMR [46]. The structure of the protein/ligand complex was
determined using intermolecular NOE-derived distance restraints.
Calculation of Electrostatic Potential
The DelPhi [47] program was used to calculate electrostatic poten-
tial by solving the linear form of the PBE. Manipulation of the poten-
tial map was done using the Delphi viewer module of UCSF Chimera
[48] and Grasp [49]. The van der Waals radii and atomic charges
were taken from the CHARMM22 parameter set. The program pa-
rameters used were as follows: interior dielectric, 2; exterior dielec-
tric, 80; solvent probe radius, 1.4 A˚; and ionic strength, 0.150 M.
Computational Docking
Docking of ligands to the CBP BRD was performed using AutoDock
v3.0.5 [39], which uses a genetic algorithm as a global optimizer
combined with energy minimization as a local search method. In
this method, the target protein is kept to be rigid and represented
as a grid, while torsional flexibility is allowed in the ligand. Mass-cen-
tered (blind-docking) as well as binding-site-centered affinity grid
maps were generated with 0.375 A˚ spacing using the Autogrid pro-
gram for the protein target. Blind-docking was used to evaluate the
accuracy of prediction of correct binding site, which was determined
based on NMR binding results. The Lamarckian genetic algorithm
(LGA) and pseudo-Solis and Wets method were used for minimiza-
tion. Default parameters for Autodock calculations were used, ex-
cept for what is otherwise stated. Particularly, for blind-docking,
each grid map consisted of a 126 3 126 3 126 grid, with the center
of the map assigned to the geometric center of the protein. Each
LGA job consisted of 50 runs with 270,000 generations in each run
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over, for binding-site-centered docking, a 62 3 76 3 80 grid was
generated with each LGA job that consisted of 200 runs with
270,000 generations in each run and maximum number of energy
evaluations of 5.0 3 106. Resulting docked orientations within 1.0 A˚
rmsd tolerance of each other were clustered together. Docked con-
formations were analyzed using AutoDockTools (http://www.
scripps.edu/wsanner) and LIGPLOT [50].
Structures of chemical ligands were generated using molecular
modeling software SYBYL v6.7 (Tripos Associated, Inc., St. Louis,
MO). Partial atomic charges were assigned using the Gasteiger-
Marsili method [51]. The program Autotors was used to define tor-
sional degrees of freedom in ligands. All the possible torsions
were allowed. The coordinates used in the Autodock calculation
were taken from the first model of NMR structures of CBP BRD/
p53-AcK382 peptide complex (PDB 1JSP) [23]. For the docking pur-
pose, the peptide coordinates were removed. Kollman united-atom
partial charges and solvation parameters were added to the protein
file using AutoDockTools.
J Surface Calculation
J surface calculation was performed using the program Jsurf, origi-
nally developed by McCoy and coworkers [38] and latter modified
and kindly provided by G. Moyna (The University of the Sciences,
Philadelphia, PA). This program quantifies effect of spatial depen-
dence of aromatic ring current field (from a ligand) on local magnetic
fields of neighboring spins at the ligand binding site within the target
protein. Assuming chemical shift perturbation observed at a protein
proton i, Di, where Di = d
i
bound2 d
i
free, is generated mainly by aromatic
ring current effect from the ligand; the origin of Di can be approxi-
mated by a single-point dipole located at the center of the ligand ar-
omatic ring, and therefore Di = d
i
bound2 d
i
freez
Bdip
R3
i

12 3cos2 qi

,
where Ri is the length of the vector from the center of the ligand ring
to the perturbed protein atom i, qi is the angle between the ring plane
normal and Ri, and Bdip is a proportionality constant. The calculation
of J surface requires an input file containing absolute change in
chemical shift for backbone amide proton of perturbed residues.
Only residues with D R |0.05| were used for the calculation. The Di
information was translated into the ligand localization using spheri-
cal dot density representation, done by the program Jsurf.
MD Simulation
MD simulation of the CBP BRD was done using Gromacs 3.2.1 [52]
and GROMOS96 (v. 43a1) force field [53]. As starting geometry, the
first model of NMR structures of the CBP BRD (PDB 1JSP; without
the peptide) was used. The protein was centered in a periodic cubic
simulation box with a minimum protein-box distance of 1.0 nm and
a volume of 351.03 nm3. The box was filled with 10,969 SPC water
molecules [54]. One Na+ was added to ensure charge neutrality of
the simulation cell. The MD protocol used the LINCS method [55]
to constrain covalent bond lengths. Temperature and pressure
were kept constant separately by coupling the protein, ions, and sol-
vent to external temperature and pressure baths with the respective
coupling constant (t) of 0.1 ps and 0.5 ps. The reference temperature
was adjusted to 300 K. To relax the solvent configuration, a steepest
descent minimization was adopted. The following step was posi-
tion-restrained dynamics, which restrains atom positions of the pro-
tein while letting the solvent move in the simulation box to reach
equilibrium before a full molecular dynamics simulation starts.
Long-range electrostatics was calculated with the Particle-Mesh
Ewald (PME) method [56, 57]. The MD time step was set at 0.002 ps.
After equilibration, the simulation time used was 5 ns.
Estimation of Backbone Amide S2 Order Parameters
from the Protein Structure
The S2 order parameter of protein backbone amide vectors was cal-
culated from the protein 3D structure using an analytical relationship
[40]. The method relates S2 of amide vector of residue i to close con-
tacts experienced by the amide proton and carbonyl oxygen of the
preceding residue i-1 with heavy atoms k:
S2i =tanh
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+bwhere rOi21;k is the distance from the carbonyl oxygen of residue i-1 to
the heavy atom k, and rHi;k is the distance between the amide proton
and the heavy atom k. The parameter b was set to20.1, considering
that the value of order parameter for rigid protein region typically is
about 0.9. A python-based script that uses MMTK [58] was used
for the calculation (http://nmr.clarku.edu/software/S2/s2predict.
html).
Fluorescence Binding Experiment
Fluorescence measurements were performed on an ISS PC1 pho-
ton-counting spectrofluorometer at room temperature. The concen-
tration of the protein (calculated using the theoretical absorption co-
efficient of 24,750 M21cm21 at 280 nm) was 5 mM in 100 mM
phosphate buffer (pH 6.5) containing 5 mM DTT. Protein intrinsic
fluorescence was measured at an excitation wavelength of 295 nm,
and emission was collected from 300–500 nm using 8 nm band
passes for both excitation and emission. The protein sample was ti-
trated with a ligand MS7972, to a final concentration of 80 mM with
0.7% final dilution.
In Vitro Protein-Peptide Binding Assay
GST-fusion CBP BRD (10 mM) was incubated with an N-terminal bio-
tinylated p53 AcK382 peptide (50 mM) in a 50 mM Tris buffer (pH 7.5),
containing 50 mM NaCl, 0.1% BSA, and 1 mM DTT, at 22ºC for 2 hr.
Streptavidin-agarose beads were added to the mixture and washed
in the Tris buffer containing 500 mM NaCl and 0.1% NP-40. The CBP
BRD eluted from the beads was run on SDS-PAGE, and visualized in
Western blots by anti-GST antibody and horseradish peroxidase-
conjugated goat anti-rabbit IgG. Small-molecule inhibition assay
was performed by incubating the CBP BRD and the biotinylated
p53 AcK382 peptide with increasing amounts of small-molecule
compound.
p53 Expression and Functional Assays
Wild-type p53-expressing U2OS cells were either incubated with
DMSO or treated with 20 or 200 mM of various small-molecule com-
pounds for about 16 hr. The cells were further incubated with 0.1 mg/
ml doxorubicin for a specified time of 2 to 24 hr, and then cell lysates
were subjected to immunoblotting analysis using specific antibod-
ies for p53, phosphorylated Ser15 of p53, acetylated Lys382 of
p53, p21, or Ku70. For the upregulation of HIF1a, U2OS cells were
incubated in the absence or presence of 200 mM of MS2126 for
16 hr, and then further incubated in either normoxic or hypoxic con-
ditions for an additional 24 hr. Cell lysates were then subjected to im-
munoblotting with the specific antibodies for HIF1a and Ku70.
Supplemental Data
Supplemental Data, including Table S1 and Figures S1–S3, are avail-
able at http://www.chembiol.com/cgi/content/full/13/1/81/DC1/.
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